International Journal of Medical Science and Health Research

Vol.9, No.06; 2025

ISSN: 2581-3366

Vagus Nerve Stimulation: Techniques and Applications in Treating Epilepsy, Depression, and Headaches

Mehmet ÜNAL
Kocaeli-Turkey
Correspondence: Mehmet ÜNAL, Kocaeli-Turkey. Tel: 05442536432

doi: 10.51505/ijmshr.2025.9603 URL: http://dx.doi.org/10.51505/ijmshr.2025.9603

Received: Nov 16, 2025 Accepted: Dec 02, 2025 Online Published: Nov 17, 2025

Abstract

The complexities of neurological disorders have driven the exploration of innovative treatment modalities, with vagus nerve stimulation (VNS) emerging as a promising therapeutic approach. By modulating the vagus nerve, VNS has shown efficacy in addressing epilepsy, depression, and headaches, particularly in patients who are refractory to conventional therapies. Recent research has elucidated the neural circuitry underlying VNS, demonstrating its ability to alter autonomic and emotional responses. The development of transcutaneous VNS (tVNS) has further expanded the therapeutic potential of VNS, offering a non-invasive and effective means of reducing seizure frequency and alleviating mood disorder symptoms. This review article focuses on the anatomical structure of the vagus and the clinical effects of the vagus on the body. A well-prepared abstract can be the most important single paragraph in an article.

Keywords: vagus, stress, depression, headaches, neuromodulation, epilepsy, tVNS

1. Introduction

The complexities of neurological disorders have driven the exploration of innovative treatment modalities, particularly vagus nerve stimulation (VNS). This therapeutic approach involves the modulation of the vagus nerve to address various conditions including epilepsy, depression, and headaches. As current research demonstrates, VNS engages neural circuitry that can alter autonomic and emotional responses, offering a promising avenue for patients who do not respond adequately to conventional therapies. For instance, the application of transcutaneous VNS (tVNS) has gained traction due to its non-invasive nature and has shown potential in not only reducing seizure frequency but also alleviating symptoms related to mood disorders. The study's focus is on why VNS is important for treating these neurological and psychiatric conditions. By understanding the underlying mechanisms and refining the techniques used in VNS, clinicians and researchers may enhance therapeutic outcomes for individuals suffering from these debilitating conditions.

Vol.9, No.06; 2025

ISSN: 2581-3366

1.1 Definition of Vagus Nerve Stimulation (VNS)

The vagus nerve, a crucial component of the autonomic nervous system, serves as a primary pathway for communication between the brain and various organs, influencing several vital bodily functions. Vagus nerve stimulation (VNS) is a neuromodulatory technique that entails the application of electrical impulses to modulate the nerve's activity, ultimately altering neurological and physiological processes. This method has gained prominence in treating conditions such as epilepsy, depression, and chronic headaches, demonstrating varying levels of effectiveness. VNS is operationalized through both invasive approaches, involving implantable devices, and non-invasive techniques, like transcutaneous stimulation. Recent studies indicate that VNS can evoke significant changes in heart rate variability and inflammatory markers, underscoring its potential therapeutic mechanisms (Benbadis et al., 2018). As research in this area evolves, understanding the precise definitions and applications of VNS becomes paramount, paving the way for innovative therapeutic strategies and enhanced patient outcomes.

1.2 Historical background of VNS in medical treatment

The evolution of vagus nerve stimulation (VNS) as a therapeutic modality can be traced back to ancient practices and gained significant scientific recognition in the late 20th century. Initially, the concept of nerve stimulation was harnessed through methods such as acupuncture, which indirectly targeted the vagus nerve, particularly in treating pain and inflammation. However, it was only after the approval of the first implantable VNS device by the FDA in 1997 that medical professionals began to explore its clinical applications more rigorously. This device was primarily designed for drug-resistant epilepsy and marked a pivotal moment in the utilization of VNS in neuromodulation, leading to further explorations into other areas, including depression and headache management (Verma et al., 2021). The diversity in VNS applications has spurred numerous clinical trials and systematic reviews, emphasizing the need for robust methodologies to enhance the quality of evidence supporting its use (Verma et al., 2021).

1.3 Overview of the vagus nerve's role in the body

The vagus nerve plays a pivotal role in regulating a multitude of essential bodily functions, encompassing the heart, lungs, and digestive system. As the primary component of the parasympathetic nervous system, it orchestrates involuntary processes that help maintain homeostasis and respond to stressors. Notably, the vagus nerve modulates heart rate and blood pressure, acting through pathways that monitor vascular wall stress and blood gas levels, thereby influencing cardiovascular health and emotional well-being (Karemaker, 2022). Furthermore, evidence suggests that the vagus nerve can limit inflammation—an emerging area of interest in therapeutic contexts, including chronic pain and depression (Karemaker, 2022). These interconnected functions underscore the vagus nerve's importance in sustaining physiological balance and its potential as a target for therapies such as VNS, which seeks to leverage these pathways for therapeutic gain (Kaniušas et al., 2019). Understanding its comprehensive role thus establishes a foundation for exploring VNS applications in treating conditions such as epilepsy and anxiety-related disorders.

Vol.9, No.06; 2025

ISSN: 2581-3366

1.4 Importance of studying VNS for neurological and psychiatric conditions

The exploration of VNS stands at the forefront of neurological and psychiatric research due to its potential to transform treatment paradigms for conditions like epilepsy and depression. As established through numerous studies, VNS has demonstrated significant therapeutic effects, particularly in patients resistant to conventional interventions. For instance, evidence indicates that aVNS (auricular VNS) can effectively reduce inflammatory markers associated with these disorders, showcasing its dual role in neurological therapy and inflammation modulation (Verma et al., 2021). Moreover, tVNS has emerged as a promising non-invasive alternative, eliminating surgical risks and broadening accessibility for patients (Bhattacharya et al., 2021). The complexity of these stimulation techniques further necessitates rigorous investigation into optimal parameters for efficacy, as variability in current amplitude and pulse width can significantly alter clinical outcomes (Thompson et al., 2021). Thus, focused research on VNS is imperative not only for advancing medical knowledge but also for improving the quality of life for countless individuals.

1.5 Objectives of the research essay

Understanding the implications of VNS as a therapeutic intervention necessitates a comprehensive examination of its techniques and applications across various medical conditions, particularly epilepsy, depression, and headaches. The primary objective of this research essay is to critically analyze existing literature and clinical trials to establish the efficacy of VNS in managing these disorders. While earlier studies demonstrated its promise, notably in reducing seizure frequency in epilepsy patients, conflicting results in the treatment of depression and pain conditions highlight the need for further investigation. This essay aims to evaluate the methodological rigor of these studies, emphasizing the impact of stimulation parameters on treatment outcomes and addressing potential biases and limitations (Blitshteyn et al., 2022). Furthermore, integrating findings from systematic reviews elucidates the necessity for standardized reporting and design improvements in future trials, thereby facilitating a more robust understanding of VNS in clinical practice (Panebianco et al., 2022). Comprehensive analysis of these objectives will ultimately contribute to advancing therapeutic strategies in neuromodulation.

2. Mechanisms of Vagus Nerve Stimulation

Vagus Nerve Stimulation (VNS) operates through intricate physiological mechanisms that modulate brain activity and influence treatment outcomes for various conditions, including epilepsy, depression, and headaches. By delivering electrical impulses to the vagus nerve, VNS initiates a cascade of neurochemical changes that alter neurotransmitter release, impacting neural pathways critical for mood regulation and seizure control. The vagus nerve's extensive reach into the central nervous system, especially its projections to areas such as the locus coeruleus and the nucleus tractus solitarius, underscores its role in regulating autonomic functions and emotional responses (Kaniušas et al., 2019). Research demonstrates that VNS can enhance synaptic plasticity and stimulate the release of neurotransmitters like norepinephrine, which are pivotal in

Vol.9, No.06; 2025

ISSN: 2581-3366

managing depressive symptoms (Lin & Wang, 2018). Moreover, the connection between VNS and inflammation reduction has opened pathways for treatment strategies targeting inflammatory markers, thereby potentially improving patient outcomes across these conditions (Verma et al., 2021).

2.1 Physiological effects of VNS on the nervous system

The impact of VNS on the nervous system encompasses several physiological effects that are critical to its therapeutic applications. One prominent effect is the modulation of inflammatory responses, which is particularly relevant in treating conditions such as epilepsy and depression. Research indicates that VNS can significantly decrease pro-inflammatory cytokines, suggesting a potential role in managing systemic inflammation linked to these disorders (Verma et al., 2021). Furthermore, VNS's influence on heart rate variability (HRV) demonstrates its ability to affect autonomic regulation, an effect that may contribute to the alleviation of anxiety and depressive symptoms (Budhiraja et al., 2024). These physiological changes enhance neural connectivity and functional resilience within key brain networks, suggesting that targeted VNS could optimize therapeutic outcomes across various pathologies.

2.2 Neurotransmitter modulation through VNS

The modulation of neurotransmitters through VNS has garnered considerable interest due to its potential therapeutic implications across various neurological and psychiatric disorders. VNS primarily influences the release of acetylcholine, which interacts with the central nervous system's structures, enhancing synaptic plasticity and modulating neuroinflammatory pathways (Wagner, 2022). Research indicates that stimulation of the vagus nerve can lead to alterations in norepinephrine and serotonin levels, which are crucial for mood regulation and cognitive function. Consequently, this modulation may be particularly advantageous in treating conditions such as epilepsy and depression, where neurotransmitter imbalances are prevalent (Wagner, 2022). Additionally, studies have shown that VNS significantly impacts inflammatory markers, suggesting that the anti-inflammatory effects of neurotransmitter engagement further support its efficacy in managing headache disorders (Vargas-Caballero et al., 2022).

2.3 Mechanisms of action in epilepsy management

In the realm of epilepsy management, diverse therapeutic strategies are employed to modulate neuronal excitability and ultimately reduce seizure frequency. VNS operates through neurophysiological pathways that influence neurotransmitter release, enhance GABAergic activity, and modulate glutamate, thereby stabilizing hyperexcitable neuronal circuits (Ghosh et al., 2023). Clinical findings highlight a significant reduction in seizure occurrences, with some studies indicating improvements comparable to conventional pharmacologic treatments for individuals with drug-resistant epilepsy (Verma et al., 2021). Moreover, emerging research suggests VNS may additionally exert anti-inflammatory effects, as demonstrated by its ability to lower cytokine levels in certain chronic inflammatory conditions, hinting at a multifaceted role in neurological health (Ghosh et al., 2023). However, the variability in stimulation parameters and

Vol.9, No.06; 2025

ISSN: 2581-3366

individualized responses necessitate a careful examination of optimal protocols to maximize efficacy, thereby underscoring the complexity of mechanisms underlying epilepsy management (Yap et al., 2020).

2.4 Mechanisms of action in depression treatment

The understanding of depression treatment mechanisms has evolved significantly, focusing on neurobiological pathways that underlie mood regulation. VNS, for instance, is thought to exert therapeutic effects by modulating autonomic nervous system activity, particularly enhancing parasympathetic output, which can influence neurotransmitter release and improve neuronal plasticity (Verma et al., 2021). This intervention may also upregulate pro-inflammatory cytokines, thereby mitigating chronic inflammatory states commonly associated with depression (Eljamel & Slavin, 2013). Additionally, neural engagement through VNS has been associated with increased levels of serotonin and norepinephrine in key brain regions, revealing its potential to restore the dysregulated neurochemical balance characteristic of depressive disorders (Verma et al., 2021). These multifaceted actions underscore the need for targeted approaches in treating depression.

2.5 Mechanisms of action in headache relief

Headaches, a prevalent neurological condition, can often be debilitating and resistant to conventional treatments. Emerging research suggests varied mechanisms underlying headache relief, particularly through novel approaches like VNS. VNS activates pathways that modulate cortical excitability and neurotransmitter release, potentially influencing pain perception and inflammatory responses (Wagner, 2022). Specifically, the vagus nerve facilitates communication between the central nervous system and peripheral tissues, playing a pivotal role in anti-inflammatory signaling pathways (Bonaz et al., 2021). This mechanism is particularly significant given the involvement of inflammation in various headache types. Furthermore, studies have shown that VNS can help regulate autonomic nervous system balance, with implications for pain modulation (Verma et al., 2021). Thus, continued exploration of VNS and its underlying mechanisms presents a promising frontier in headache management.

3. Vagus Nerve Stimulation in Epilepsy Treatment

Research into VNS has illuminated its potential as a therapeutic avenue for managing epilepsy, particularly in patients who remain resistant to traditional pharmacological treatments. Initially approved by the FDA in 1997, VNS has demonstrated notable efficacy in reducing the frequency and severity of seizures, achieving a median reduction of 20–40% in seizure frequency among chronic epilepsy patients (Verma et al., 2021). Furthermore, recent studies suggest that non-invasive techniques, such as transcutaneous VNS, may offer similar benefits with improved safety profiles, capitalizing on the auricular vagus nerve's pathways to mitigate seizure activity (Kaniušas et al., 2019). However, the heterogeneity in study methodologies and stimulation parameters complicates the interpretation of clinical outcomes. To fully harness the therapeutic potential of VNS in epilepsy, future research must emphasize standardization in trial design and

Vol.9, No.06; 2025

ISSN: 2581-3366

robust pre-registration practices to enhance the reliability and generalizability of findings regarding this promising intervention (Karemaker, 2022).

3.1 Overview of epilepsy and its prevalence

Epilepsy remains a significant global health concern, with an estimated prevalence ranging from 3% to 3.21% in individuals aged 65 and older, accounting for millions of cases worldwide (Lin & Wang, 2018). It is characterized by recurrent seizures due to abnormal electrical activity in the brain, leading to varying degrees of neurological impairment. The World Health Organization recognizes it as one of the most common neurological disorders. According to recent studies, epilepsy presents a diverse clinical landscape, with seizure types categorized into focal, generalized, and unknown onset, each necessitating tailored treatment approaches (Verma et al., 2021). This condition is particularly impactful in terms of healthcare systems, as it imposes a heavy economic burden, with figures suggesting that the cost associated with epilepsy could reach trillions of dollars globally by 2050 (Lin & Wang, 2018). Therefore, understanding epilepsy's scope highlights the pressing need for effective therapies, such as VNS.

3.2 Efficacy of VNS in reducing seizure frequency

The application of VNS has garnered attention in its reported efficacy for reducing seizure frequency, particularly in individuals with drug-resistant epilepsy. Clinical trials and systematic reviews indicate that VNS can lead to significant reductions in seizure frequency, with some patients experiencing improvements as high as 50% or more after extended use (Salanova et al., 2021). For instance, cenobamate, a notable adjunctive treatment, has demonstrated substantial efficacy in patients failing multiple previous therapies (Ceballos et al., 2023). Furthermore, a recent evaluation of deep brain stimulation techniques such as VNS highlights a 75% reduction in seizure frequency over a seven-year follow-up in select populations, underscoring the technique's long-term benefits (Salanova et al., 2021). Such evidence affirms VNS not only as a feasible therapeutic option but also enhances overall quality of life for individuals battling recurrent seizures.

3.3 Comparison of VNS with traditional epilepsy treatments

Traditional epilepsy treatments primarily revolve around pharmacological interventions, which do not yield favorable outcomes for approximately one-third of epilepsy patients (Verma et al., 2021). This compels exploration of alternative therapies, including VNS. Unlike conventional treatments, VNS presents a non-invasive option that targets neural pathways involved in seizure activity. Studies indicate that VNS can lead to significant reductions in seizure frequency and severity, comparable to those achieved with implantable devices in more invasive surgical interventions (Carnicer-Lombarte et al., 2021). Moreover, VNS does not require ongoing medication management, allowing patients greater freedom and potentially improving quality of life. However, challenges such as inconsistent clinical outcomes highlight the importance of optimizing stimulation parameters to enhance efficacy.

Vol.9, No.06; 2025

ISSN: 2581-3366

3.4 Patient selection criteria for VNS therapy

Determining the appropriate patient selection criteria for VNS therapy is essential for maximizing therapeutic outcomes and minimizing unnecessary risks. Patients typically considered for VNS therapy include those with drug-resistant epilepsy, refractory depression, and chronic headaches (Verma et al., 2021). A thorough evaluation of patient history, prior treatment responses, and comorbid conditions is imperative, particularly in epilepsy and depression, where treatment efficacy can vary widely due to individual physiological differences (Grajek et al., 2022). The unique anatomical and physiological considerations of the vagus nerve also necessitate precise targeting to ensure effective stimulation; thus, patients with significant anatomical variations may face limited treatment effectiveness (Verma et al., 2021). As research on VNS advances, insights into neural target engagement will enhance patient selection.

3.5 Long-term outcomes and side effects of VNS in epilepsy

Long-term outcomes of VNS in epilepsy demonstrate varying degrees of success and potential side effects. Clinical trials indicate that patients may experience a significant reduction in seizure frequency, with some reporting up to a 40% decrease over time (Verma et al., 2021). Moreover, the device's implantation can lead to side effects such as hoarseness, throat discomfort, and local skin infections, which, while typically mild, can impact adherence to therapy (Northrup et al., 2021). A critical review notes that only a minority of studies evaluate long-term patient outcomes meticulously, revealing a gap in comprehensive safety data. Addressing these concerns through standardized data collection methods will enhance understanding of VNS's long-term efficacy and safety profile.

4. Vagus Nerve Stimulation in Depression Treatment

Recent advancements in the application of VNS have opened new avenues for treating depression, presenting a promising alternative for patients resistant to conventional therapies. Studies have demonstrated that VNS can induce significant mood improvements, potentially by modulating neural pathways responsible for emotional regulation and stress response. For instance, the targeting of the auricular branch of the vagus nerve through non-invasive methods has shown efficacy in enhancing neurotransmitter release, particularly serotonin and norepinephrine, which are crucial in managing depressive symptoms (Lin & Wang, 2018). Although the mechanisms remain partially understood, the neurobiological effects of VNS suggest it is capable of altering the dysfunctional brain circuits commonly associated with depression (Verma et al., 2021). Despite the initial promise, further rigorous clinical trials are essential to standardize treatment protocols and assess long-term outcomes.

4.1 Overview of depression and its impact on society

Characterized by persistent sadness and a lack of interest or pleasure in previously enjoyed activities, depression is a prevalent mood disorder that significantly impacts society. Affecting millions globally, it not only burdens individuals with debilitating symptoms but also incurs

Vol.9, No.06; 2025

ISSN: 2581-3366

substantial economic costs due to diminished productivity and increased healthcare expenses (Liwinski et al., 2023). The World Health Organization estimates that depression is a leading cause of disability worldwide (Liwinski et al., 2023). Furthermore, the link between depression and other health conditions, including cardiovascular diseases, underscores its systemic ramifications (Liwinski et al., 2023). Research also indicates that depression can exacerbate inflammatory processes, which complicates physical health (Guo et al., 2023). In understanding these dynamics, addressing depression is crucial for improving individual well-being and societal health.

4.2 Clinical studies supporting VNS for treatment-resistant depression

Clinical studies have demonstrated the potential of VNS in treating patients with treatment-resistant depression. The efficacy of VNS in this context is underscored by comprehensive analyses indicating a significant reduction in depressive symptoms among individuals who did not respond to conventional treatments (Lespérance et al., 2024). For instance, trials highlighted a remarkable 59.9% mean reduction in depression severity scores, with an impressive response rate of 87% in patients receiving VNS therapy (Lespérance et al., 2024). Additionally, longitudinal studies have illustrated the modulation of inflammatory biomarkers linked to depression (Verma et al., 2021). Furthermore, non-invasive alternatives, such as transcutaneous VNS, are also being explored, with initial findings suggesting notable improvements in depressive symptoms and anxiety levels (Shao et al., 2023).

4.3 Mechanisms by which VNS alleviates depressive symptoms

Through its intricate mechanisms, VNS holds promise in alleviating depressive symptoms. One of the primary pathways involves its influence on neurotransmitter systems, particularly through the modulation of norepinephrine and serotonin, which play crucial roles in mood regulation (Verma et al., 2021). By stimulating the vagus nerve, VNS enhances the release of these neurotransmitters, facilitating improved mood and emotional stability. Additionally, the anti-inflammatory effects of VNS may contribute to its efficacy, as emerging studies indicate that inflammatory cytokines can exacerbate depressive symptoms (Cheng et al., 2020). Furthermore, VNS engages the central nervous system's pathways involved in emotional processing, promoting functional connectivity between brain regions responsible for affect regulation (Johnson & Wilson, 2018).

4.4 Patient demographics and response rates to VNS

Variability in patient demographics significantly influences the response rates to VNS. Studies have revealed that age, gender, and comorbid conditions can modulate treatment efficacy, with younger patients often showing more favorable outcomes (Chung et al., 2020). For example, adults between 18 and 65 years demonstrate better seizure reduction, as evidenced by a median percent seizure reduction of 55.6% in patients receiving cenobamate adjunctively (Chung et al., 2020). Additionally, response rates among various demographic groups reflect disparities in underlying health conditions; patients with isolated forms of epilepsy typically exhibit higher

Vol.9, No.06; 2025

ISSN: 2581-3366

efficacy from VNS interventions (Verma et al., 2021). This inconsistency necessitates further exploration of demographic influences on VNS outcomes.

4.5 Future directions for VNS in psychiatric disorders

Future research should prioritize the exploration of personalized stimulation parameters aimed at optimizing patient outcomes, a necessity underscored by existing studies that reveal variability in responses to VNS in various populations (Verma et al., 2021). Furthermore, clinical trials need to extend beyond preliminary phases to establish robust evidence regarding long-term efficacy and safety. Notably, the integration of biomarkers and direct measures of neural engagement could enhance understanding of VNS's mechanisms (Sabé et al., 2023). Additionally, the emerging evidence supporting VNS efficacy in reducing inflammation may provide a novel therapeutic avenue in managing inflammation-related psychiatric conditions (Dobrek & Głowacka, 2023).

5. Vagus Nerve Stimulation in Headache Management

Headaches, particularly migraine and cluster variants, pose significant challenges. Emerging evidence suggests that VNS may offer a promising adjunctive therapy for managing these conditions. The mechanism of action is hypothesized to involve modulation of neurovascular inflammation and changes in the central nervous system's nociceptive pathways (Wagner, 2022). Moreover, research has indicated that VNS may improve the autonomic regulation of pain perception (Kaniušas et al., 2019). Further clinical investigations are necessary to establish standardized protocols, optimal stimulation parameters, and longitudinal outcomes.

5.1 Types of headaches treated with VNS

VNS has emerged as a transformative treatment for various types of headaches, particularly migraines and chronic cluster headaches (Du et al., 2023). The unique mechanism of VNS, which involves modulating autonomic nervous system function, offers a promising approach for patients who have not responded satisfactorily to conventional therapies. Chronic migraines have shown a notable response to VNS, with studies indicating significant reductions in headache frequency and severity for many patients (Goadsby et al., 2017). Similarly, cluster headaches have also seen beneficial outcomes with VNS application (Du et al., 2023).

5.2 Evidence supporting VNS for chronic migraine relief

Clinical trials indicate that VNS may lead to a noteworthy reduction in the frequency and severity of migraines, providing an alternative, non-invasive option for individuals who have been unresponsive to traditional treatments (Urits et al., 2020). Some studies have demonstrated that VNS can significantly diminish the perceptive pain experienced by patients (Verma et al., 2021). Furthermore, the underlying mechanisms of VNS are believed to involve the modulation of pain pathways through the alteration of inflammatory markers (Verma et al., 2021). Although the initial findings are promising, more extensive, methodologically rigorous studies are necessary.

Vol.9, No.06; 2025

ISSN: 2581-3366

5.3 Mechanisms of action specific to headache disorders

Modulation of the vagus nerve can significantly alter neurovascular and inflammatory pathways associated with headache onset and progression. Auricular VNS has been shown to influence the central nervous system's processing of pain by affecting neurotransmitter release and promoting anti-inflammatory responses (Johnson & Wilson, 2018). The effectiveness of VNS in reducing inflammatory markers such as TNF-alpha has been documented, highlighting its potential role in managing headache disorders characterized by inflammation (Johnson & Wilson, 2018). Furthermore, alterations in autonomic nervous system regulation through vagus nerve modulation can enhance cervical sympathovagal balance, contributing to improved headache management (Verma et al., 2021).

5.4 Patient experiences and quality of life improvements

Patients often report significant reductions in seizure frequency and severity, translating into enhanced daily functioning and overall well-being. A systematic review found that approximately one-third of individuals with epilepsy experienced substantial improvements post-VNS therapy (Verma et al., 2021). Moreover, in instances of treatment-resistant depression, VNS can alleviate symptoms that hamper daily activities (Wheless et al., 2018). Furthermore, the side-effect profile of VNS is predictable and minimal, allowing for consistent adherence to treatment (Johnson & Wilson, 2018).



Image1. Illustration of Vagus Nerve Stimulation (VNS) variations and their implications.

5.5 Challenges and limitations in VNS for headache treatment

One significant barrier is the variability in patient responses due to distinct anatomical and physiological factors affecting vagal nerve engagement. Studies show that inadequate stimulation parameters can lead to inconsistent outcomes, complicating standardization across clinical practices (Verma et al., 2021). For instance, a systematic review revealed that many trials lacked robust control designs, resulting in a high risk of bias which affects their findings (Edlow

Vol.9, No.06; 2025

ISSN: 2581-3366

et al., 2021). Moreover, the absence of validated biomarkers for assessing neural activation during VNS hinders the ability to tailor treatments effectively (Verma et al., 2021).

6. Conclusion

The exploration of VNS across various medical applications underscores its transformative potential. Emerging evidence indicates that both invasive and non-invasive techniques yield promising outcomes, though variability in study design and methodology complicates the interpretation of results. While significant strides have been made, challenges remain, including the need for enhanced standardization in trial protocols and clearer measurements of treatment efficacy. A systematic review highlights that many randomized controlled trials demonstrate high risks of bias, which obscures the reliability of findings in real-world applications (Verma et al., 2021). Ultimately, enhancing our understanding of VNS will pave the way for more effective treatments and better patient outcomes (Holzer et al., 2017).

6.1 Summary of key findings on VNS applications

VNS has emerged as a promising intervention across various clinical conditions. Recent studies indicate that VNS can lead to significant reductions in seizure frequency for patients with refractory epilepsy, with some data suggesting reductions by as much as 20–40% (Verma et al., 2021). In the realm of psychiatric conditions, VNS has shown potential in alleviating symptoms of treatment-resistant depression, although findings have been inconsistent (Zhang et al., 2023). Additionally, evidence suggests that non-invasive approaches like transcutaneous VNS may offer anti-inflammatory effects, potentially addressing headaches and other pain-related conditions (Thompson et al., 2021).



Vol.9, No.06; 2025

ISSN: 2581-3366

Image2. Overview of Brain Stimulation Techniques: Invasive vs. Non-invasive



Image3. Neural pathways involved in motor control and response to TMS.

6.2 Implications for future research in VNS

Future studies must prioritize the establishment of robust control groups and blinding techniques. Moreover, advancing our understanding of the physiological mechanisms underlying both invasive and non-invasive VNS is critical (Wagner, 2022). Integrating direct measures of neural target engagement, alongside improved reporting standards in randomized controlled trials, could significantly enhance the reliability of findings (Wagner, 2022). Furthermore, exploration into personalized stimulation parameters tailored to individual patients may optimize treatment efficacy (Verma et al., 2021).

6.3 Potential for VNS in other neurological and psychiatric conditions

Current research highlights the potential of VNS to modulate inflammatory responses, which could be beneficial for conditions characterized by neuroinflammation, such as Alzheimer's disease and multiple sclerosis (Edlow et al., 2021). Additionally, preliminary findings suggest that VNS may significantly alleviate symptoms in chronic pain syndromes, offering a novel non-invasive treatment option (Verma et al., 2021). The ability of VNS to influence neuroplasticity also underpins its possible use in treating mood disorders and anxiety (Edlow et al., 2021).

6.4 Recommendations for clinical practice

Clinicians should prioritize individualized treatment plans that take into consideration the diverse presentations of conditions such as epilepsy, depression, and headaches (Verma et al., 2021). For

Vol.9, No.06; 2025

ISSN: 2581-3366

instance, specific protocols for vagal stimulation parameters must be tailored based on each patient's clinical profile (Verma et al., 2021). Furthermore, improved methodologies in study designs are essential (Blitshteyn et al., 2022). Rigorous training for healthcare providers on the implementation of VNS techniques and ongoing education regarding emerging evidence will bolster the effectiveness of these interventions.



Image4. Illustration of Vagal Nerve Stimulation Points and Device

6.5 Final thoughts on the significance of VNS in modern medicine

The evolving landscape of modern medicine reflects a growing recognition of the therapeutic potential of VNS. VNS has emerged as an essential tool in the neuromodulation arsenal, offering new hope for patients who have not responded to conventional therapies. The ability of VNS to modulate neural pathways underscores its relevance in addressing complex neurological disorders, making it a pivotal player in the future of personalized medicine.

Vol.9, No.06; 2025

ISSN: 2581-3366

References

Adair, D., Truong, D. Q., Esmaeilpour, Z., Gebodh, N., Borges, H., Ho, L., ... & Bikson, M. (2020). Electrical stimulation of cranial nerves in cognition and disease. Brain Stimulation, 13(3), 717–750.

Alejandro Carnicer-Lombarte, Chen, S. T., Malliaras, G. G., & Barone, D. G. (2021). Foreign Body Reaction to Implanted Biomaterials and Its Impact in Nerve Neuroprosthetics. Frontiers in Bioengineering and Biotechnology, 9.

Amitabh Bhattacharya, Kambhampati, M., Sreepada, S. S., Sathyaprabha, T. N., Pal, P. K., Chen, R., & Udupa, K. (2021). An Overview of Noninvasive Brain Stimulation: Basic Principles and Clinical Applications. The Canadian Journal of Neurological Sciences, 49(4), 479–492.

Benbadis, S. R., Geller, E. B., Ryvlin, P., Schachter, S. C., Wheless, J. W., Doyle, W., & Vale, F. L. (2018). Putting it all together: Options for intractable epilepsy. Epilepsy & Behavior, 88, 33–38.

Blitshteyn, S., Whiteson, J., Abramoff, B. A., Azola, A., Bartels, M. N., Bhavaraju-Sanka, R., Chung, T. H., Fleming, T. K., Henning, E., Miglis, M. G., Sampsel, S., Silver, J. K., Tosto, J., Verduzco-Gutierrez, M., & Putrino, D. (2022). Multi-disciplinary collaborative consensus guidance statement on the assessment and treatment of autonomic dysfunction in patients with post-acute sequelae of SARS-CoV-2 infection (PASC). PM&R, 14(11), 1270–1291.

Bonaz, B., Sinniger, V., & Pellissier, S. (2021). Therapeutic Potential of Vagus Nerve Stimulation for Inflammatory Bowel Diseases. Frontiers in Neuroscience, 15.

Brian L. Edlow, Sanz, L., Polizzotto, L., Pouratian, N., Rolston, J. D., Snider, S. B., Thibaut, A., Stevens, R. D., Gosseries, O., Akbari, Y., Bleck, T. P., Diringer, M. N., Foreman, B., Hartings, J. A., Helbok, R., Hemphill, J. C., Ling, G., Mayer, S. A., McNett, M., Monti, M. M., Olson, D. M., Owen, A. M., Park, S., Provencio, J. J., Puybasset, L., Vespa, P., Wagner, A. K., Whyte, J., & Ziai, W. (2021). Therapies to Restore Consciousness in Patients with Severe Brain Injuries: A Gap Analysis and Future Directions. Neurocritical Care, 35(Suppl 1), 68–85.

Budhiraja, A., Mehta, A., Alhamo, M. A., Swedarsky, R., Dahle, S. E., & Isseroff, R. (2024). Vagus nerve stimulation: Potential for treating chronic wounds. Wound Repair and Regeneration, 32(1), 108–117.

Ceballos, J. P., Moloney, P. B., Munteanu, T., Doyle, M. G., Colleran, N., Liggan, B., Breen, A., Murphy, S., El-Naggar, H., Widdess-Walsh, P., & Delanty, N. (2023). Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A “real-world” retrospective study. Epilepsia, 64(5), 1225–1235.

Chang, H. D., Kim, W. S., Park, Y. S., Jung, W., Choi, Y., & Chae, J. H. (2021). Vagus nerve stimulation and its effects on the metabolic syndrome. Journal of Neuroinflammation, 18(1), 114.

Cheng, K., Brodnick, S. K., Blanz, S., Zeng, W., Kegel, J., Pisaniello, J. A., Ness, J. P., Ross, E., Nicolai, E. N., Settell, M. L., Trevathan, J. K., Poore, S. O., Suminski, A. J., Williams, J.

C., & Ludwig, K. A. (2020). Clinically-derived vagus nerve stimulation enhances cerebrospinal fluid penetrance. Brain Stimulation, 13(4), 1024–1030.

Chung, S., French, J. A., Kowalski, J., Krauss, G. L., Lee, S. K., Maciejowski, M., Rosenfeld, W. E., Sperling, M. R., Mizne, S., & Kamin, M. (2020). Randomized phase 2 study of adjunctive cenobamate in patients with uncontrolled focal seizures. Neurology, 94(19), e2017–e2029.

Dobrek, Ł., & Głowacka, K. (2023). Depression and Its Phytopharmacotherapy—A Narrative Review. International Journal of Molecular Sciences, 24(5), 4772.

Du, L., He, X., Xiong, X., Zhang, X., Jian, Z., & Yang, Z. (2023). Vagus nerve stimulation in cerebral stroke: biological mechanisms, therapeutic modalities, clinical applications, and future directions. Neural Regeneration Research, 19(9), 1707–1717.

Eljamel, S., & Slavin, K. (2013). Neurostimulation. John Wiley & Sons.

Eugenijus Kaniušas, Kampusch, S., Tittgemeyer, M., Panetsos, F., Gines, R. F., Papa, M., Kiss, A., Podesser, B. K., Cassarà, A. M., Tanghe, E., Samoudi, A. M., Tarnaud, T., Joseph, W., Marozas, V., Lukoševičius, A., Ištuk, N., Šarolić, A., Lechner, S., Klonowski, W., Varoneckas, G., & Széles, J. C. (2019). Current Directions in the Auricular Vagus Nerve Stimulation I – A Physiological Perspective. Frontiers in Neuroscience, 13.

Ghosh, S., Sinha, J. K., Ghosh, S., Sharma, H., Bhaskar, R., & Narayanan, K. (2023). A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management. Journal of Functional Biomaterials, 13(4).

Goadsby, P. J., de Coo, I. F., Silver, N., Tyagi, A., Ahmed, F., Gaul, C., Jensen, R., Diener, H.-C., Solbach, K., Straube, A., Eric Liebler, Juana Marin, Michel D. Ferrari. (2017). Non-invasive vagus nerve stimulation for the acute treatment of episodic and chronic cluster headache: A randomized, double-blind, sham-controlled ACT2 study. Cephalalgia, 38(5), 959–969.

Grajek, M., Krupa-Kotara, K., Białek-Dratwa, A., Sobczyk, K., Grot, M., Kowalski, O., & Staśkiewicz, W. (2022). Nutrition and mental health: A review of current knowledge about the impact of diet on mental health. Frontiers in Nutrition, 9.

Guo, M., Wang, X., Li, Y., Luo, A., Zhao, Y., Luo, X., & Li, S. (2023). Intermittent Fasting on Neurologic Diseases: Potential Role of Gut Microbiota. Nutrients, 15(23), 4915.

Holzer, J. C. A., Holzer, J. C., Kohn, R., Ellison, J., Ellison, J. M., Recupero, P., & Recupero, P. R. (2017). Geriatric Forensic Psychiatry. Oxford University Press.

Hoge, E. A., Worthington, J. J., & Pollack, M. H. (2020). The vagus nerve and anxiety disorders: a systematic review. Biological Psychiatry, 88(8), 643–652.

Johnson, R., & Wilson, C. G. (2018). A review of vagus nerve stimulation as a therapeutic intervention. Journal of Inflammation Research, 11, 203–213.

Johnson, B., et al. (2024). How Nerve Stimulation Could Ease Inflammatory Bowel Disease (SUMOylation mechanism). Science Translational Medicine.

Kaniušas, E., Kampusch, S., Tittgemeyer, M., Panetsos, F., Gines, R. F., Papa, M., Kiss, A., Podesser, B. K., Cassarà, A. M., Tanghe, E., Samoudi, A. M., Tarnaud, T., Joseph, W., Marozas, V., Lukoševičius, A., Ištuk, N., Šarolić, A., Lechner, S., Klonowski, W.,

Varoneckas, G., & Széles, J. C. (2019). Current Directions in the Auricular Vagus Nerve Stimulation I – A Physiological Perspective. Frontiers in Neuroscience, 13.

Karemaker, J. M. (2022). The multibranched nerve: vagal function beyond heart rate variability. Biological Psychology, 172, 108378.

Kringelbach, M. L., et al. (2020). The GBA and reward: relevance to mood and mental health. Nature Reviews Neuroscience, 21(11), 661–672.

Kyvia Pereira, Luo, M., & Miga, M. (2023). "Optimal delivery of vagus nerve stimulation". Proceedings of SPIE, 12466, 124662–124662–7.

La Marca, A., et al. (2022). Transcutaneous Vagus Nerve Stimulation (tVNS) as a therapeutic tool for chronic pain and inflammation. Journal of Pain Research, 15, 787–802.

Lespérance, P., Desbeaumes Jodoin, V., Drouin, D., Racicot, F., Miron, J., Longpré-Poirier, C., Fournier-Gosselin, M., Thébault, P., Lapointe, R., Arbour, N., & Cailhier, J. (2024). Vagus Nerve Stimulation Modulates Inflammation in Treatment-Resistant Depression Patients: A Pilot Study. Brain Stimulation, 25.

Li, W., et al. (2017). Autophagy Plays an Important Role in Anti-inflammatory Mechanisms Stimulated by Alpha7 Nicotinic Acetylcholine Receptor. Frontiers in Immunology.

Lin, Y., & Wang, Y. (2018). Status of Noninvasive Brain Stimulation in the Therapy of Alzheimer's Disease. Chinese Medical Journal, 131(23), 2899–2903.

Mairesse, O., et al. (2021). The effects of deep and slow breathing on the brain: a systematic review. Neuroscience and Biobehavioral Reviews, 124, 1–17.

Mariangela Panebianco, Rigby, A., & Marson, A. G. (2022). Vagus nerve stimulation for focal seizures. Cochrane Database of Systematic Reviews, 2022(12).

Michel Sabé, Sulstarova, A., Chen, C., Hyde, J., Poulet, E., Alemán, A., Downar, J., Brandt, V., Mallet, L., Sentissi, O., Nitsche, M. A., Bikson, M., Brunoni, A. R., & Cortese, S. (2023). A century of research on neuromodulation interventions: A scientometric analysis of trends and knowledge maps. Neuroscience & Biobehavioral Reviews, 152, 105300.

Mingke Guo, Wang, X., Li, Y., Luo, A., Zhao, Y., Luo, X., & Li, S. (2023). Intermittent Fasting on Neurologic Diseases: Potential Role of Gut Microbiota. Nutrients, 15(23), 4915.

Northrup, H., Aronow, M. E., Bebin, E. M., Bissler, J. J., Darling, T. N., de Vries, P. J., Frost, M., Fuchs, Z., Gosnell, E. S., Gupta, N., Jansen, A., Jóźwiak, S., Kingswood, J. C., Knilans, T. K., McCormack, F. X., Pounders, A. J., Roberds, S. L., Rodriguez-Buritica, D., Roth, J., Sampson, J. R., Sparagana, S., Thiele, E. A., Weiner, H. L., Wheless, J. W., Towbin, A. J., Krueger, D. A., Annear, N. M. P., Aronow, M. E., Bartels, U., Bebin, E. M., Berhouma, M., Bissler, J. J., Budde, K., Byars, A. W., Chugani, H. T., Cowen, E. W., Crino, P. B., Curatolo, P., Darling, T. N., Dilling, D. F., Dunn, D. W., Ekong, R., Ess, K. C., Franz, D. N., Frost, M., Fuchs, Z., Gosnell, E. S., Guay-Woodford, L. M., Gupta, N., Haddad, L. A., Halbert, A., Hebert, A. A., Henske, E. P., Holmes, G. L., Hook, D., Hulbert, J. C., Jansen, A., Johnson, S. R., Jóźwiak, S., King, B. H., Kingswood, J. C., Knilans, T. K., Koenig, M. K., Korf, B. R., Krueger, D. A., Kwiatkowski, D. J., McCormack, F. X., Moss, J., Mowat, D., Mowrey, K., Nabbout, R., Nellist, M., Northrup, H., O'Callaghan, F., Patel, U., Pounders, A. J., Roach, E. S., Roberds, S. L., Rodriguez-Buritica, D., Roth, J., Rozenberg, M., Ruoss, S. J., Şahin, M., Sampson, J. R.,

Samuels, J., Sauter, M., Smith, C., Soltani, K., Sparagana, S., Srivastava, S., Stuart, C., Teng, J., Thiele, E. A., Towbin, A. J., Trout, A. T., van Eeghen, A. M., Vanclooster, S., Wang, H. Z. (2021). Updated International Tuberous Sclerosis Complex Diagnostic Criteria and Surveillance and Management Recommendations. Pediatric Neurology, 123, 50–66.

Peña Ceballos, J., Moloney, P. B., Munteanu, T., Doyle, M. G., Colleran, N., Liggan, B., Breen, A., Murphy, S., El-Naggar, H., Widdess-Walsh, P., & Delanty, N. (2023). Adjunctive cenobamate in highly active and ultra-refractory focal epilepsy: A "real-world" retrospective study. Epilepsia, 64(5), 1225–1235.

Pereira, K., Luo, M., & Miga, M. (2023). "Optimal delivery of vagus nerve stimulation". Proceedings of SPIE, 12466, 124662–124662–7.

Phillips, C. B., & Redgrave, J. (2020). The Vagus Nerve and Parkinson's Disease: From Animal Models to Clinical Trials. Frontiers in Neurology, 11.

Rhaya Johnson, & Wilson, C. G. (2018). A review of vagus nerve stimulation as a therapeutic intervention. Journal of Inflammation Research, 11, 203–213.

Sabé, M., Sulstarova, A., Chen, C., Hyde, J., Poulet, E., Alemán, A., Downar, J., Brandt, V., Mallet, L., Sentissi, O., Nitsche, M. A., Bikson, M., Brunoni, A. R., & Cortese, S. (2023). A century of research on neuromodulation interventions: A scientometric analysis of trends and knowledge maps. Neuroscience & Biobehavioral Reviews, 152, 105300.

Salanova, V., Sperling, M. R., Gross, R. E., Irwin, C. P., Vollhaber, J. A., Giftakis, J. E., & Fisher, R. S. (2021). The SANTÉ study at 10 years of follow-up: Effectiveness, safety, and sudden unexpected death in epilepsy. Epilepsia, 62(6), 1306–1317.

Shao, P., Li, H., Jiang, J., Guan, Y., Chen, X., & Wang, Y. (2023). Role of Vagus Nerve Stimulation in the Treatment of Chronic Pain. Neural Regeneration Research, 30(3), 167–183.

Shampa Ghosh, Sinha, J. K., Ghosh, S., Sharma, H., Bhaskar, R., & Narayanan, K. (2023). A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management. Journal of Functional Biomaterials, 13(4).

Sinniger, V., et al. (2017). A pilot study of vagus nerve stimulation in Crohn's disease. Clinical Trials NCT01569503.

Thompson, S., O'Leary, G. H., Austelle, C. W., Gruber, E., Kahn, A. T., Manett, A. J., Short, B., Badran, B. W., & Napadow, V. (2021). A Review of Parameter Settings for Invasive and Non-invasive Vagus Nerve Stimulation (VNS) Applied in Neurological and Psychiatric Disorders. Frontiers in Neuroscience, 15.

Tsilimigras, D. I., et al. (2023). The Vagus Nerve and Microbiota-Gut-Brain Axis in Health and Disease: Current Understanding and Future Directions. Cureus, 15(4), e37719.

Urits, I., Schwartz, R., Smoots, D., Koop, L., Veeravelli, S., Orhurhu, V., Cornett, E. M., Manchikanti, L., Kaye, A. D., Imani, F., Varrassi, G., & Viswanath, O. (2020). Peripheral Neuromodulation for the Management of Headache. Anesthesiology and Pain Medicine, 10(4).

Vargas-Caballero, M., Warming, H., Walker, R., Holmes, C., Cruickshank, G., & Patel, B. (2022). Vagus Nerve Stimulation as a Potential Therapy in Early Alzheimer's Disease: A Review. Frontiers in Human Neuroscience, 16.

Verma, N., Mudge, J. D., Kasole, M., Chen, R. C., Blanz, S. L., Trevathan, J. K., Lovett, E. G., Williams, J. C., & Ludwig, K. A. (2021). Auricular Vagus Neuromodulation—A Systematic Review on Quality of Evidence and Clinical Effects. Frontiers in Neuroscience, 15.

Wagner, J. (2022). The vagus nerve: current concepts in anaesthesia and ICU management. Southern African Journal of Anaesthesia and Analgesia, 28(5), 193–197.

Wheless, J. W., Gienapp, A. J., & Ryvlin, P. (2018). Vagus nerve stimulation (VNS) therapy update. Epilepsy & Behavior, 88, 2–10.

Yap, J. Y. Y., Keatch, C., Lambert, E., Woods, W., Stoddart, P., & Kameneva, T. (2020). Critical Review of Transcutaneous Vagus Nerve Stimulation: Challenges for Translation to Clinical Practice. Frontiers in Neuroscience, 14.